Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 0.68 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.63 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.63 |
| ▸ | ABL1 | P00519 | 7/20 | 0.57 |
| ▸ | SRC | P12931 | 7/20 | 0.57 |
| ▸ | MTOR | P42345 | 7/20 | 0.57 |
| ▸ | PRKDC | P78527 | 7/20 | 0.57 |
| ▸ | EGFR | P00533 | 6/20 | 0.57 |
| ▸ | HCK | P08631 | 6/20 | 0.57 |
| ▸ | KDR | P35968 | 6/20 | 0.57 |
| ▸ | EPHB4 | P54760 | 6/20 | 0.57 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9884082 | 0.93 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL9884124 | 0.92 | PIK3CG (0.74) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL9884116 | 0.91 | PIK3CD (0.64) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL9884073 | 0.90 | PIK3CG (0.82) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL20725920 | 0.89 | PIK3CD (0.74) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL9884115 | 0.88 | PIK3CD (0.73) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL9884096 | 0.88 | PIK3CD (0.87) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL9884094 | 0.87 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL19418809 | 0.86 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL20725918 | 0.85 | PIK3CG (0.80) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111153905-A | PI3K protein kinase inhibitors, in particular delta inhibitors and/or gamma inhibitors | 理森制药股份公司 | 2020-05-15 | — | — | CN | claimed |
| EP-3016955-A1 | PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS | Rhizen Pharmaceuticals S.A. (CH) | 2016-05-11 | — | — | EP | claimed |
| WO-2015001491-A1 | PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS | RHIZEN PHARMACEUTICALS SA (CH) | 2015-01-08 | — | — | WO | claimed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11433065-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2022-09-06 | — | — | US | disclosed |
| EP-3613743-B1 | PROCESSES FOR THE PREPARATION OF 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES | INTELLIKINE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3441392-B1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | INTELLIKINE LLC (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3811974-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | Infinity Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20200222384-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2012-09-27 | — | — | US | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8193182-B2 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | INTELLIKINE, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193182-B2 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | INTELLIKINE, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | PIK3CD 4/4885PIK3CG 2/4885PIK3CA 1/4885 |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | PIK3CD 4/4885PIK3CG 2/4885PIK3CA 1/4885 |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | PIK3CD 7/4885PIK3CG 8/4885PIK3CA 1/4885 |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | PIK3CD 6/4885PIK3CG 15/4885PIK3CA 1/4885 |
| US-20200222384-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | PIK3CD 7/4885PIK3CG 8/4885PIK3CA 1/4885 |
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | PIK3CD 5/4885PIK3CG 9/4885PIK3CA 1/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | PIK3CD 4/4885PIK3CG 6/4885PIK3CA 1/4885 |
| US-11433065-B2 | Certain chemical entities, compositions and methods | PIK3CA, AKT3, PIK3C2A | PIK3CD 7/4885PIK3CG 8/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.